IL33 and COVID-19: However, in pathological conditions such as severe COVID-19, elevated sST2 acts as a decoy receptor, neutralizing IL-33 and disrupting its protective functions, thereby promoting myocardial damage, fibrosis, and ventricular dysfunction [20].